Exscientia (NASDAQ:EXAI – Get Rating) will post its quarterly earnings results before the market opens on Wednesday, May 24th. Investors interested in registering for the company’s conference call can do so using this link.
Exscientia (NASDAQ:EXAI – Get Rating) last released its earnings results on Thursday, March 23rd. The company reported ($0.38) earnings per share for the quarter. The company had revenue of $8.20 million for the quarter, compared to analysts’ expectations of $17.51 million. Exscientia had a negative net margin of 428.70% and a negative return on equity of 21.76%. On average, analysts expect Exscientia to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Exscientia Stock Performance
Shares of EXAI opened at $6.04 on Monday. The business has a 50-day simple moving average of $5.55 and a two-hundred day simple moving average of $6.06. The company has a quick ratio of 6.04, a current ratio of 6.05 and a debt-to-equity ratio of 0.02. Exscientia has a 52 week low of $4.09 and a 52 week high of $16.45. The stock has a market cap of $730.16 million, a price-to-earnings ratio of -4.31 and a beta of 0.38.
Wall Street Analysts Forecast Growth
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Exscientia during the 1st quarter valued at $58,000. Softbank Group CORP. purchased a new position in shares of Exscientia during the 1st quarter valued at $30,114,000. Geode Capital Management LLC lifted its stake in shares of Exscientia by 17.1% during the 1st quarter. Geode Capital Management LLC now owns 18,767 shares of the company’s stock valued at $99,000 after buying an additional 2,735 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Exscientia by 215.7% during the 1st quarter. Renaissance Technologies LLC now owns 84,600 shares of the company’s stock valued at $448,000 after buying an additional 57,800 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Exscientia by 396.8% during the 1st quarter. Bank of America Corp DE now owns 25,296 shares of the company’s stock valued at $134,000 after buying an additional 20,204 shares in the last quarter. Hedge funds and other institutional investors own 22.36% of the company’s stock.
Exscientia Company Profile
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
- Get a free copy of the StockNews.com research report on Exscientia (EXAI)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.